EUROPEAN SYMPOSIUM

Optimal use of clotting factors and immunoglobulins
26-27 April 2013, Wildbad Kreuth, Germany
Duration: 2.5 days. Working language: English

PROGRAMME

THURSDAY 25 APRIL 2013
16:00-18:00
- Poster set-up for manufacturers
- Registration for participants
- Pre-meeting for speakers
19:00-21:30
- Buffet Dinner

FRIDAY 26 APRIL 2013
8:00 Welcome
Dr Karl-Heinz Buchheit, EDQM, Council of Europe

SESSION 1: General information on the clinical use of clotting factors and immunoglobulins
Moderator: Karl-Heinz Buchheit
Rapporteurs: Rainer Seitz & Harvey Klein

8:15-8:30 Key lecture
Optimal clinical use of blood and plasma derivatives
Background and perspectives
Harvey Klein, National Institute of Health, Bethesda, USA

8:30-9:15 Rationale for the meeting
Clinical use of immunoglobulins
Hans-Hartmut Peter, University of Freiburg, DE
Clinical use of clotting factors (plasma-derived and recombinant)
Wolfgang Schramm, University of Munich, DE
Regulations for plasma-derived and recombinant medicinal products
Rainer Seitz, Paul Ehrlich Institut, Langen, DE

9:15-9:30 Clinical challenges and access to clotting factor concentrates in haemophilia in Europe
Paul Giangrande, Churchill Hospital, Oxford, UK

9:30-9:45 Current data on the use of clotting factors and immunoglobulins in Europe
Patrick Robert, The Marketing Research Bureau, Inc, Orange, USA

9:45-10:00 Report on the outcome of the EDQM surveys
Karin Berger, University Hospital of Munich, DE
Jacqueline Kerr, Paul-Ehrlich-Institut, Langen, DE

10:00-10:30 Coffee break and poster viewing
### SESSION 2: Clotting Factors

**Moderators & Rapporteurs:** Wolfgang Schramm & Rainer Seitz

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Institution/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30-10:45</td>
<td>Patients organisations’ view - Access and unmet needs</td>
<td>Brian O’Mahony, European Haemophilia Consortium (EHC)</td>
<td>City, Country</td>
</tr>
<tr>
<td>10:45-11:05</td>
<td>New developments in clinical research and new treatment modalities – A clinician’s perspective</td>
<td>Pier Mannucci, IRCCS Ca’ Granda Maggiore Policlinico Hospital Foundation</td>
<td>Milan, IT</td>
</tr>
<tr>
<td>11:05-11:25</td>
<td>Benefits and limitations with innovative clotting factor preparations</td>
<td>Flora Peyvandi, University of Milan</td>
<td>IT</td>
</tr>
<tr>
<td>11:25-11:45</td>
<td>European clinical guidelines</td>
<td>Cedric Hermans, Cliniques Universitaires Saint Luc</td>
<td>BE</td>
</tr>
<tr>
<td>11:45-12:00</td>
<td>European regulatory perspective</td>
<td>Anneliese Hilger, Paul Ehrlich Institut</td>
<td>Langen, DE</td>
</tr>
<tr>
<td>12:00-12:15</td>
<td>Registries</td>
<td>Mike Makris, Royal Hallamshire Hospital</td>
<td>Sheffield, UK</td>
</tr>
<tr>
<td>12:15-13:30</td>
<td>Lunch break and poster viewing</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### SESSION 3: Immunoglobulins

**Moderators & Rapporteurs:** Hans-Harmut Peter, Isabella Quinti & Carrock Sewell

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Institution/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30-13:45</td>
<td>Patients Organisations’ view - Access and unmet needs</td>
<td>Jose Drabwell, International Patient Organisation for Primary Immunodeficiencies</td>
<td></td>
</tr>
<tr>
<td>13:45-14:05</td>
<td>Clinically established indications in primary and secondary immunodeficiencies</td>
<td>Helen Chapel, John Radcliffe Hospital</td>
<td>Oxford, UK</td>
</tr>
<tr>
<td></td>
<td></td>
<td>presented by Hans-Harmut Peter</td>
<td></td>
</tr>
<tr>
<td>14:05-14:25</td>
<td>Immunomodulation: On-label and off-label Usage</td>
<td>Ivo Van Schaik, University of Amsterdam</td>
<td>NL</td>
</tr>
<tr>
<td>14:25-14:40</td>
<td>European regulatory perspective</td>
<td>Jacqueline Kerr, Paul Ehrlich Institut</td>
<td>Langen, DE</td>
</tr>
<tr>
<td>14:40-14:55</td>
<td>Demand Management Plan</td>
<td>Carrock Sewell, Scunthorpe General Hospital</td>
<td>UK</td>
</tr>
<tr>
<td>14:55-15:10</td>
<td>Innovative products and new developments - cancelled</td>
<td>Lennart Hammarström, Karolinska Institute</td>
<td>Stockholm, SE</td>
</tr>
<tr>
<td>15:10-15:25</td>
<td>Registries</td>
<td>Bodo Grimbacher, University of Freiburg</td>
<td>DE</td>
</tr>
<tr>
<td>15:25-16:00</td>
<td>Coffee break and poster viewing</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SESSION 4: Working Groups Session

16:00-18:00 Working Group 1: Clotting factors
Moderators: Pier Mannucci, Wolfgang Schramm
Rapporteurs: Pier Mannuci, Paul Giangrande, Wolfgang Schramm

16:00-18:00 Working Group 2: Immunoglobulins
Moderators: Hans-Hartmut Peter, Jacqueline Kerr
Rapporteurs: Hans-Hartmut Peter, Jacqueline Kerr, Isabella Quinti & Carrock Sewell

18:00 Close of meeting

20:00 Evening Dinner

SATURDAY 27 APRIL 2013 – CLOSED MEETING

8:00-9:00 Interim reports from Working Groups

9:00-10:45 Discussion in the Working Groups

10:45-11:00 Coffee break

11:00-12:30 Final reports from the Working Groups
Moderators: Rainer Seitz & Karl-Heinz Buchheit

- Working Group 1: Clotting factor
- Working Group 2: Immunoglobulins

12:30-13:30 Lunch break

13:30-16:00 Conclusions and Recommendations

SCIENTIFIC PROGRAMME COMMITTEE

Prof Dr Rainer SEITZ Ms Karin BERGER
Dr Marie-Emmanuelle BEHR-GROSS Dr Anneliese HILGER
Dr Karl-Heinz BUCHHEIT Dr Jacqueline KERR
Prof Dr Wolfgang SCHRAMM Prof Dr Hans-Hartmut PETER